Extraordinary General Meeting of Q-Med AB (publ)

Extraordinary General Meeting of Q-Med AB (publ) 

The Extraordinary General Meeting of Q-Med AB (publ) with regard to the
resolution concerning the new Board took place on February 4, 2009 at 3 p.m.

The meeting adopted the resolution to re-elect Bertil Hult, Anders Milton and
Bengt Ågerup for the period up until the end of the next Annual General Meeting.
Ulf Mattson, Tomas Nicolin and Kristina Persson were elected as new members of
the Board.

The meeting also elected Anders Milton as Chairman of the Board.   


Queries should be addressed to: 
Madelene Sandgren, Director Investor Relations and Corporate Communications,
Tel: + 46 (0)70 974 90 15

Q-Med AB is a rapidly growing and profitable biotechnology/medical device
company. The company develops, manufactures, markets, and sells primarily
medical implants. The majority of the products are based on the company's
patented technology, NASHA™, for the production of stabilized non-animal
hyaluronic acid. The product portfolio today contains: Restylane® for filling
lines and folds, contouring and creating volume in the face, Macrolane™ for body
contouring, Durolane™ for the treatment of osteoarthritis of the hip and knee
joints, Deflux® for the treatment of vesicoureteral reflux, VUR, (a malformation
of the urinary bladder) in children, and Solesta™ for the treatment of fecal
incontinence. Sales are made through the company's own subsidiaries or
distributors in over 70 countries. Q Med today has just over 700 coworkers, with
close to 500 at the company's head office and production facility in Uppsala,
Sweden. Q-Med AB is listed in the Mid Cap segment of the OMX Nordic Exchange in
Stockholm.


Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate
identity number 556258-6882.
Tel: +46(0)18-474 90 00. Fax: +46(0)18-474 90 01. E-mail: info@q-med.com. Web:
www.q-med.com.

In USA, Q-Med AB's affiliate is the wholly-owned subsidiary Q-Med Scandinavia,
Inc.